Navigation Links
Double assault on tough types of leukemias
Date:9/20/2012

Investigators at Northwestern University Feinberg School of Medicine have identified two promising therapies to treat patients with acute megakaryocytic leukemia (AMKL), a rare form of leukemia where the number of cases is expected to increase with the aging population.

The disease is characterized by an overload of white blood cells that remain forever young because they can't mature into specialized cells. Published in a recent issue of the journal Cell, the study found that the drug with the generic name alisertib (MLN8237), induced division and growth of healthy cells to overtake the proliferation or "blasts" of immature cells.

In the study, a mouse model with this leukemia that was treated with alisertib showed a striking reduction in the number of leukemia cells, including dramatic reductions in overwhelming white cell counts and the weights of their spleens and livers, which are indications of leukemia.

Alisertib has been tested before in humans with limited success to treat other types of leukemia and lymphoma, a cancer of the immune system. However, the drug should be effective against AKML in humans because it specifically targets the enzyme Aurora A kinase, said study senior author John Crispino, the Robert I. Lurie, MD, and Lora S. Lurie Professor of Hematology/Oncology at Feinberg. In normal cell development, this enzyme enables healthy cells to proliferate correctly, but with leukemia, is also allows adolescent cells to multiply unchecked if they are in the mix.

Crispino also is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

"Alisertib was really potent against the proliferation of cancer cells," Crispino said. "We were incredibly excited when we found that the drug we predict will reverse AMKL is already far along in clinical development. The fact that we don't have to start from scratch means we could be years closer to finding an effective therapy."

Crispino expects alisertib will be a more gentle cancer drug without the ravaging side effects of conventional chemotherapies. This is because the drug specifically targets a key enzyme, avoids healthy cells in the bone marrow and blood, and will probably be more effective at lower doses than drugs tested in previous studies.

"This study has given us a scientific rationale to take this drug to an early phase clinical trial in this very challenging form of leukemia," said Jessica Altman, M.D., assistant professor in hematology/oncology at Feinberg and an oncologist at Northwestern Memorial Hospital. Altman also is a member of the Lurie Cancer Center. Together with other leukemia specialists, she is designing a multi-center clinical trial planned to open in 2013.

Investigators also identified another attack plan for other types of leukemias. Sifting through 9,000 chemical compounds during the study, they found that dimethylfasudil boosted the number of mature bone marrow cells and shot down malignant ones.

Dimethylfasudil could be useful against AMKL and tolerated better by patients, Crispino says. However, he adds that alisertib is moving forward now because there is urgent need and the drug is available. Meanwhile, Crispino's team and other scientists at Northwestern's Center for Molecular Innovation and Drug Discovery are developing the compound dimethylfasudil into an acceptable anticancer drug for clinical trials, which may take two to three years.

Investigators believe dimethylfasudil may be valuable to fight other types of leukemias because it has broad action against other enzymes that let cancer cells reproduce.


'/>"/>

Contact: Marla Paul
Marla-Paul@northwestern.edu
312-503-8928
Northwestern University
Source:Eurekalert

Related medicine news :

1. Early Menopause May Double Heart Disease Risk, Study Says
2. Double drug combo could shut down abnormal blood vessel growth that feeds disease
3. Adding bavituximab to second-line chemotherapy doubles response rate
4. MRSA cases in academic hospitals double in 5 years: study
5. Snacking and BMI linked to double effect of brain activity and self-control
6. Moms Pot Use Doubles Risk of Preemie Birth: Study
7. Osteoarthritis risk not diminished in double bundle ACL surgeries
8. As Obesity Rates Rise, Cases of Kidney Stones Double: Study
9. Common acne medication doubles risk of eye infection
10. Study finds number of battery-related emergency department visits by children more than doubles
11. Obesitys Health Costs Double Earlier Estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent ... cancer deaths. More than 10,000 people are expected to die of melanoma this year. The ... the one of the most commonly diagnosed cancers in young women. A recent breakthrough in ...
(Date:4/29/2016)... ... April 29, 2016 , ... Reltok Nasal Products proudly announces that Boston ... and neck/ear, nose and throat specialty, has added the KOTLER NASAL AIRWAY™ to its ... is a newly patented safety device secured by nasal surgeons onto the floor ...
(Date:4/29/2016)... ... April 29, 2016 , ... Innovations with Ed Begley ... upcoming episode, airing third quarter 2016 via Discovery Channel. Dates and show times ... Dairy Products, located in Greenwood, Wisconsin applies product research and development and continuous ...
(Date:4/29/2016)... ... April 29, 2016 , ... The infertility specialists at ... Sanaz Ghazal, and Dr. Daniel A. Potter -- are proud of the recent release ... Technology (SART). In April, SART published the latest verified data for 375 ...
(Date:4/29/2016)... ... April 29, 2016 , ... International Dehydrated Foods, Inc. (IDF™) will attend ... 4 at the Doubletree by Hilton Hotel in Oak Brook, Illinois. The two-day event ... technologies for protein ingredients. , At the seminar, IDF™ will offer samples of its ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  Marking its one year anniversary ... ovarian cancer risk test, Color Genomics ... that highly impact the most common hereditary cancers ... Color Test analyzes hereditary cancer risks for breast, ... cancers. The Color Test is physician ordered and ...
(Date:4/28/2016)... YORK , April 28, 2016  The blood ... 275 million dollars, according to Kalorama Information and The ... typing, immunoassays and nucleic acid testing.  The healthcare research ... made progress in developing blood collection stations and in ... made in Kalorama Information,s report, Blood Testing ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
Breaking Medicine Technology: